Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good activity, but side effects may limit its use.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.
Immunotherapy did not improve overall survival but led to fewer side effects and better quality of life.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
Half of people with worse liver function responded well to immunotherapy.
Recommendations now include multiple systemic medications in addition to surgery and local therapies.
A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.